Skip to content

Released Aug 7, 2025, after the close

10-Q filed Aug 8, 2025, 39 days after period end · 0000950170-25-105284

Q2 2025 · 10-Q
Revenue—
Net Income-$2.44MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$28.04N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$2,461,229N/M
Operating Cash Flowderived-$1,919,281N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Net Income-$2.44M-$8.39M-$1.45M-$1.83M
EPS Diluted-$28.04-$246.27-$5.83-$4.16

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR